![Aharon Schwartz](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Aharon Schwartz
Président chez
BIOLINERX LTD.
Fortune : 742 101 $ au 30/06/2026
Profil
Aharon Schwartz currently works at BioLineRx Ltd., as Chairman from 2004, BioCancell Therapeutics, Inc., as Chairman from 2011, BioMAS Ltd., as Chairman, Amorphical Ltd., as Chairman, D Pharm Ltd., as Chairman, Protalix Biotherapeutics, Inc., as Independent Director from 2014, Protalix Ltd., as Director, Medingalil Ltd., as Director, Barcode Diagnostics Ltd., as Director from 2018, and Anthill Ventures, as Partner.
Dr. Schwartz also formerly worked at DenX Medical Software Systems Ltd., as Chairman, Yissum Research Development Co. Ltd., as Chairman, Univo Pharmaceuticals Ltd., as Chairman from 2013 to 2016, Meytav Technological Enterprises Innovation Center Ltd., as Chairman, VYNE Pharmaceuticals Ltd., as Director from 2015 to 2020, Anchiano Therapeutics Ltd., as Director from 2011 to 2013, Alcobra Ltd., as Independent Director from 2014 to 2017, Peptor Ltd, as Non-Executive Director, TransPharma Medical Ltd., as Non-Executive Director, MediWound Ltd., as Director, CureTech Ltd., as Director, Andromeda Biotech Ltd., as Director, Integra Holdings Ltd., as Director, Scopus Biopharma, Inc., as Director, Teva Pharmaceutical Industries Ltd., as Vice President & Head-Innovative Ventures from 2008 to 2011, and Clal Biotechnology Industries Ltd., as Consultant.
Dr. Schwartz received his graduate degree from Technion-Israel Institute of Technology, doctorate degree in 2014 from The Hebrew University of Jerusalem, undergraduate degree from The Hebrew University of Jerusalem, and doctorate degree in 1978 from Weizmann Institute of Science.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 30/04/2026 | 310 500 ( 0,39% ) | 723 465 $ | 30/06/2026 | |
BIOLINERX LTD. 0,14% | 18/03/2026 | 3 705 000 ( 0,14% ) | 18 636 $ | 30/06/2026 |
Postes actifs de Aharon Schwartz
| Sociétés | Poste | Début |
|---|---|---|
| BIOLINERX LTD. | Président | 10/05/2010 |
| PROTALIX BIOTHERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/11/2014 |
D Pharm Ltd.
 D Pharm Ltd. BiotechnologyHealth Technology Provides drug development services | Président | - |
Anthill Ventures
 Anthill Ventures Investment ManagersFinance Anthill Ventures is an active manager which invests in companies located in the United States, Israel, Singapore & India. The firm targets companies operating in the fields of health, climate and urban lifestyles. It provides financing for seed and early-stage capital requirements with investment size USD 0.075 to 0.5 million. It also makes co-investments. | Private Equity Investor | - |
Barcode Diagnostics Ltd.
 Barcode Diagnostics Ltd. Pharmaceuticals: MajorHealth Technology Develops personalized cancer medicines | Directeur/Membre du Conseil | 11/03/2018 |
Protalix Ltd. | Directeur/Membre du Conseil | - |
Medingalil Ltd. | Directeur/Membre du Conseil | - |
BioMAS Ltd.
 BioMAS Ltd. Pharmaceuticals: MajorHealth Technology Develops tellurium based drugs | Président | - |
Amorphical Ltd.
 Amorphical Ltd. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals for bone, metabolic and inflammatory diseases | Président | - |
| ░░░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Anciens postes connus de Aharon Schwartz
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░ ░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░░░░░░░░ ░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░░ ░░░░░░░░░░░ ░░░░░░░░░░ ░░░░░░ ░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Aharon Schwartz
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
69
Relations au 1er degré
29
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 29 |
|---|---|
Teva Pharmaceutical Industries Ltd.
 Teva Pharmaceutical Industries Ltd. Pharmaceuticals: GenericHealth Technology Manufactures and markets generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients | Health Technology |
VYNE Pharmaceuticals Ltd.
 VYNE Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products for dermatology, gynecology, wounds and burns and ophthalmic disorders | Health Technology |
Anchiano Therapeutics Ltd.
 Anchiano Therapeutics Ltd. BiotechnologyHealth Technology Provides biopharmaceutical services | Health Technology |
Alcobra Ltd.
 Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Develops proprietary pharmaceutical products | Health Technology |
DenX Medical Software Systems Ltd.
 DenX Medical Software Systems Ltd. Medical SpecialtiesHealth Technology Manufactures dental equipment | Health Technology |
Yissum Research Development Co. Ltd.
 Yissum Research Development Co. Ltd. Investment ManagersFinance Yissum Research invests in companies located in Israel. The firm targets companies operating across a broad range of sectors and industries. It provides financing for seed and early stage capital requirements. | Finance |
Clal Biotechnology Industries Ltd.
 Clal Biotechnology Industries Ltd. Financial ConglomeratesFinance Provides investment and support services for life science research companies | Finance |
Peptor Ltd
 Peptor Ltd Pharmaceuticals: MajorHealth Technology Develops products to treat autoimmune diseases | Health Technology |
Univo Pharmaceuticals Ltd.
 Univo Pharmaceuticals Ltd. Agricultural Commodities/MillingProcess Industries Engages in growing, manufacturing, processing, marketing and distribution of products medical cannabis | Process Industries |
Technion-Israel Institute of Technology
 Technion-Israel Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Hebrew University of Jerusalem
 The Hebrew University of Jerusalem Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
TransPharma Medical Ltd.
 TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Provides development and commercialization of drugs | Health Technology |
Weizmann Institute of Science
 Weizmann Institute of Science Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BioLineRx Ltd.
 BioLineRx Ltd. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company which develops and commercializes cell transplantation products | Health Technology |
Protalix Biotherapeutics, Inc.
 Protalix Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets recombinant therapeutic proteins | Health Technology |
MediWound Ltd.
 MediWound Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops, manufactures and commercializes bio-therapeutic solutions for tissue repair and regeneration | Health Technology |
CureTech Ltd.
 CureTech Ltd. BiotechnologyHealth Technology Operates as a biotechnology company | Health Technology |
Andromeda Biotech Ltd.
 Andromeda Biotech Ltd. Pharmaceuticals: MajorHealth Technology Develops treatment for autoimmune diabetes | Health Technology |
Meytav Technological Enterprises Innovation Center Ltd.
 Meytav Technological Enterprises Innovation Center Ltd. Investment ManagersFinance Meytav is a venture capital investment manager following a hands-on investment approach. It focuses on early-stage businesses in the life sciences sector, particularly biopharmaceuticals and medical device technology. It provides a wide range of support services to their portfolio companies, including incubator space for two to three years, office services, strategic advisory, planning and budgeting assistance, and access to an established network of business partners. Meytav targets projects based on innovation in the medical field. It leverages their close proximity with Upper Galilee research centers including MIGAL, specialized in agriculture and biotechnology, and the Tel Hai Community College. Each project is structured as an independent company co-owned by the entrepreneurs, the financing partners and Meytav's holding company. It promotes the growth of their investee companies through IP portfolio development and the establishment of partnerships for R&D, clinical development, manufacturing and commercialization worldwide. | Finance |
BioCancell Therapeutics, Inc.
 BioCancell Therapeutics, Inc. BiotechnologyHealth Technology Is a biopharmaceuticals company | Health Technology |
BioMAS Ltd.
BioMAS Ltd. Pharmaceuticals: MajorHealth Technology Develops tellurium based drugs | Health Technology |
Amorphical Ltd.
Amorphical Ltd. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals for bone, metabolic and inflammatory diseases | Health Technology |
Protalix Ltd. | |
Integra Holdings Ltd.
 Integra Holdings Ltd. MiscellaneousMiscellaneous Operates as a holding company | Miscellaneous |
Medingalil Ltd. | |
Anthill Ventures
Anthill Ventures Investment ManagersFinance Anthill Ventures is an active manager which invests in companies located in the United States, Israel, Singapore & India. The firm targets companies operating in the fields of health, climate and urban lifestyles. It provides financing for seed and early-stage capital requirements with investment size USD 0.075 to 0.5 million. It also makes co-investments. | Finance |
Barcode Diagnostics Ltd.
Barcode Diagnostics Ltd. Pharmaceuticals: MajorHealth Technology Develops personalized cancer medicines | Health Technology |
D Pharm Ltd.
D Pharm Ltd. BiotechnologyHealth Technology Provides drug development services | Health Technology |
Scopus Biopharma, Inc.
 Scopus Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company develops transformational therapeutics for serious diseases | Health Technology |
